These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 29206546)

  • 21. Geriatric pharmacology.
    Dowling PM
    Vet Clin North Am Small Anim Pract; 2005 May; 35(3):557-69. PubMed ID: 15833558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Principles of drug administration in renal insufficiency.
    Lam YW; Banerji S; Hatfield C; Talbert RL
    Clin Pharmacokinet; 1997 Jan; 32(1):30-57. PubMed ID: 9012555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine.
    Sweileh WM; Janem SA; Sawalha AF; Abu-Taha AS; Zyoud SH; Sabri IA; Al-Jabi SW; Jaradat NA; Zaid AA
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):908-12. PubMed ID: 17464934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
    Harrower AD
    Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing errors in prescribed antibiotics for older persons with CKD: a retrospective time series analysis.
    Farag A; Garg AX; Li L; Jain AK
    Am J Kidney Dis; 2014 Mar; 63(3):422-8. PubMed ID: 24189475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug dosing adjustments in patients with chronic kidney disease.
    Munar MY; Singh H
    Am Fam Physician; 2007 May; 75(10):1487-96. PubMed ID: 17555141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
    Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S
    Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment.
    Yang QJ; Jerath A; Bies RR; Wąsowicz M; Pang KS
    Biopharm Drug Dispos; 2015 Jul; 36(5):294-307. PubMed ID: 25704361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling and predicting drug pharmacokinetics in patients with renal impairment.
    Rowland Yeo K; Aarabi M; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):261-74. PubMed ID: 22115405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
    Healy MF; Speroni KG; Eugenio KR; Murphy PM
    Ann Pharmacother; 2012 Apr; 46(4):477-83. PubMed ID: 22474135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations.
    Bodge MN; Reddy S; Thompson MS; Savani BN
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):908-19. PubMed ID: 24565993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.
    MacCallum L
    Can J Diabetes; 2014 Oct; 38(5):334-43. PubMed ID: 25284697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychotropic drugs and renal failure: translating the evidence for clinical practice.
    Baghdady NT; Banik S; Swartz SA; McIntyre RS
    Adv Ther; 2009 Apr; 26(4):404-24. PubMed ID: 19444657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses.
    Yakatan GJ; Maness DD; Scholler J; Johnston JT; Novick WJ; Doluisio JT
    Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):465-82. PubMed ID: 109903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of newer drugs in patients with renal impairment (Part II).
    Singlas E; Fillastre JP
    Clin Pharmacokinet; 1991 May; 20(5):389-410. PubMed ID: 1879096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic dosing in patients with renal insufficiency or receiving dialysis.
    Cunha BA; Friedman PE
    Heart Lung; 1988 Nov; 17(6 Pt 1):612-6. PubMed ID: 3056882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implications of using the MDRD or CKD-EPI equation instead of the Cockcroft-Gault equation for estimating renal function and drug dosage adjustment in elderly patients.
    Cartet-Farnier E; Goutelle-Audibert L; Maire P; De la Gastine B; Goutelle S
    Fundam Clin Pharmacol; 2017 Feb; 31(1):110-119. PubMed ID: 27599753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.